Between Month 5 and 7, 36.4% of the study population fulfilled the criteria for retreatment and were retreated (average amount, 0.5 mL per side).
Of the 82 subjects who completed the week 78 visit evaluation, 33 (40%) fulfilled criteria for retreatment and were retreated (mean volume, 1.3 mL per side).
Of the 855 patients participating in the Italian EAP, 126 patients had disease progression following a response to ipilimumab induction therapy but did not receive retreatment and 51 patients (6%) were retreated with ipilimumab 3 mg kg−1.
Participants were retreated with ranibizumab monthly as needed (PRN), using predefined retreatment criteria.
Finally, due to the low number of patients involved who were retreated, it is not possible to evaluate the effect of retreatment on the risk of SIEs.
About one fourth of the cases were retreated in this study.
Eight of nine patients were followed for a period of 9 25 months (mean, 18 months) with two recurrences that were retreated with awake-PDL and followed for an additional 8.3 and 9.5 months without recurrence.
The PCR products were retreated with Exonuclease I and then precipitated with 75% (v/v) ethanol.
Raw fluorescence images were retreated in order to substract the membrane autofluorescence contribution to the signal.
The lysates were retreated with a 2D protein cleanup kit (Bio-Rad, Hercules, CA) and protein concentration was determined using the Bio-Rad Protein Assay kit.
Patients with convalescent stool carriage of S. typhi or S. paratyphi A were retreated according to the sensitivity of the isolate and were further followed up.
